Recent Updates
Recently added Catalysts
PRCT Positive Sentiment

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024

Key Takeaway: PROCEPT BioRobotics has announced that it will report its financial results for the third quarter of 2024 on October 28, 2024, prior to market opening. The company, which specializes in urological surgical robotics, has scheduled a conference call at 8:00 a.m. Eastern Time to discuss these results. Investors are encouraged to participate via a live webcast or by dialing in. PROCEPT BioRobotics continues to develop transformative solutions that enhance patient care, particularly through its AQUABEAM and HYDROS robotic systems.
Price reaction · baseline $74 (2024-10-08 close) · hit after-hours · clean, no other PRCT news in the window
day 0 close · peak
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Scheduled reporting of third quarter financial results indicates organizational transparency.
  • The company's focus on innovative surgical robotics solutions shows commitment to advancing patient care.
  • A strong body of clinical evidence supports the effectiveness of Aquablation therapy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~35 mo
Minimal dilution risk
Lead asset
PRO 2000
Phase 1 · HIV Infections

Full Press Release Details

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by following one of the below links:
Webcast link for interested listeners: https://edge.media-server.com/mmc/p/yhamkcsz
Dial-in registration for sell-side research analysts: https://register.vevent.com/register/BI271ff7de75a342d8941d642d1900ba40
Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.
An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
VP, Investor Relations and Business Operations

Frequently Asked Questions

When will PROCEPT BioRobotics report its Q3 2024 financial results?

PROCEPT BioRobotics will report its Q3 2024 financial results on October 28, 2024.

How can I listen to the PROCEPT conference call?

Listeners can access the conference call via a webcast link or dial-in registration.

What is unique about the HYDROS Robotic System?

The HYDROS Robotic System is the only AI-powered technology for Aquablation therapy.

Who does Aquablation therapy benefit?

Aquablation therapy benefits men with lower urinary tract symptoms due to BPH.

How long will the webcast be available for replay?

The archived webcast will be available for replay for at least 90 days.

Last updated: Oct 9, 2024